Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
IT0004147952
Mon, 18.10.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 SIX Listing Rules
Milan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received [ … ]
Mon, 18.10.2021
Newron Pharmaceuticals S.p.A.
Newron Receives Fifth Tranche from Financing Agreement with
European Investment Bank (EIB)
Milan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous syste [ … ]
Thu, 16.09.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 16, 2021, 07:00 am CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights a [ … ]
Thu, 16.09.2021
Newron Pharmaceuticals S.p.A.
Newron announces Half-Year 2021 results
Milan, Italy, September 16, 2021, 07:00 am CEST - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights and [ … ]
Mon, 06.09.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 SIX Listing Rules
Milan, Italy - September 6, 2021, 5.45 pm CEST - Newron Pharmaceutical S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received [ … ]
Mon, 06.09.2021
Newron Pharmaceuticals S.p.A.
Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
Milan, Italy - September 6, 2021, 5.45 pm CEST - Newron Pharmaceutical S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous syst [ … ]
Mon, 06.09.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 SIX Listing Rules
Evenamide has the potential to be the first add-on therapy for patients with positive symptoms of schizophrenia
Four-week, double-blind, placebo-controlled study to evaluate safety and efficacy of therapeutic dose (30mg BID)
Minimum of 200 patients to be enrolled at study centers in Europe [ … ]
Mon, 06.09.2021
Newron Pharmaceuticals S.p.A.
Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia
Evenamide has the potential to be the first add-on therapy for patients with positive symptoms of schizophrenia
Four-week, double-blind, placebo-controlled study to evaluate safety and efficacy of therapeutic dose (30mg BID)
Minimum of 200 patients to [ … ]
Thu, 20.05.2021
Newron Pharmaceuticals SpA
Milan, Italy - May 20, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that with reference to its media release of May 4, 2021, it received further Paragraph IV N [ … ]
Thu, 20.05.2021
Newron Pharmaceuticals S.p.A.
Newron announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA
Milan, Italy - May 20, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that wit [ … ]